Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Individual Patient Expanded Access to CA102N

ABSTRACT: This study is an individual patient expanded access protocol that the subject enrolled had completed the combination treatment of CA102N plus Lonsurf for at least 12 cycles.

DISEASE(S): Advanced Or Metastatic Colorectal Cancer (mcrc),Colorectal Neoplasms

PROVIDER: 2708903 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

An Expanded Access Program for AM0010 (Pegilodecakin)

Project description:This is an Expanded Access Program (EAP) available to patients who have advanced cancers, who have failed or progressed on standard of care systemic therapy and do not qualify for ongoing clinical trials.

| 2275175 | ecrin-mdr-crc

Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer

Project description:This is an expanded access program for eligible participants designed to provide access to onvansertib in combination with FOLFIRI and bevacizumab.

| 2343718 | ecrin-mdr-crc

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

Project description:The primary objective of this protocol is to provide expanded access to tabelecleucel to participants with Epstein-Barr virus-associated diseases and malignancies for whom there are no other appropriate therapeutic options, and who are not eligible to enroll in clinical studies designed to support the development and registration of tabelecleucel.

| 2218995 | ecrin-mdr-crc

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Project description:The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations who have incomplete response to or have exhausted available therapies. Ulixertinib is available for treatment as monotherapy or in combination with other clinically tolerable agent(s), conditionally approved by the drug manufacturer.

| 2352905 | ecrin-mdr-crc

Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits.

Project description:INTRODUCTION:Expanded access is the use of an investigational product by patients with serious medical conditions without participation in a clinical trial. It is a complicated process involving the collaboration of many parties and pharmaceutical companies. Ongoing efforts focus on accelerating expanded access procedures in the best interest of patients with cancer. Areas covered: We review the regulatory and ethical challenges encountered in efforts to optimize expanded access. Expert opinion: In the era of personalized medicine, patients may benefit from novel therapeutic agents that demonstrate encouraging results in early studies. However, drug approval is a lengthy and cumbersome procedure that might exceed the time frame of a life-threatening disease. Expanded access provides options to patients with unmet needs. It may provide informative safety and efficacy data to the manufacturers and the scientific and regulatory organizations. Ongoing efforts are being made by global governmental and scientific committees, regulatory agencies, and patient organizations to address the ethical and regulatory issues and to optimize the expanded access process. Their goal is to expand access to promising novel drugs for individual patients and to accelerate the necessary procedures while preserving patient safety.

| S-EPMC6291242 | biostudies-other

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

Project description:The objective of the program is to provide access to TAS-102 to patients with metastatic colorectal cancer who are refractory to or failing standard chemotherapy, are new to therapy with TAS-102 and in whom therapy with TAS-102 is clinically indicated.

| 2177942 | ecrin-mdr-crc

Expression patterns of white blood cells in response to individual food treatments relative to LPS treatment and untreated in an FPIES subject.

Project description:Total blood white blood cells from a FPIES subject were treated with individual treatmens of 2 foods that were safe for the subject (pear and breast milk), two foods that were triggers (quinoa and sweet potato), and 19 foods of unknown status for the subject. These treatments were compared to LPS treatment and untreated.

2023-01-10 | GSE222508 | GEO

Polyglutamine expanded huntingtin dramatically alters the genome-wide binding of HSF1

Project description:This SuperSeries is composed of the following subset Series: GSE38000: Polyglutamine expanded huntingtin dramatically alters the genome-wide binding of HSF1 (ChIP-Seq) GSE38001: Polyglutamine expanded huntingtin dramatically alters the genome-wide binding of HSF1 (mRNA) Refer to individual Series

2012-06-18 | E-GEOD-38002 | biostudies-arrayexpress